Table 1.

Patient clinical outcomes and tumor characteristics

	N = 1951
Histology
Invasive ductal carcinoma	152 (82.6%)
Invasive lobular carcinoma	9 (4.9%)
Other	23 (12.5%)
Not available	11 (5.6%)
Estrogen receptor positive	97 (50.3%)
Not available	2 (1%)
Progesterone receptor positive	67 (35.1%)
Not available	4 (2.05%)
Systemic disease status
Extracranial metastases	149 (76.4%)
No extracranial metastases	46 (23.6%)
Stage at diagnosis
I	25 (13.0%)
II	26 (13.5%)
III	54 (28.1%)
IV	87 (45.3%)
Not available	3 (1.5%)
Brain metastases at diagnosis	17 (8.7%)
KPS at SRS
60	4 (2.1%)
70	32 (16.7%)
80	71 (37.0%)
90	64 (33.3%)
100	21 (10.9%)
Not available	3 (1.5%)
Age at SRS	55.0 (47.4,62.0)
Intracranial progression	117 (60.0%)
Leptomeningeal dissemination	32 (16.4%)
Time to LMD, months	12.2 (5.1,22.1)
Adverse radiation events
Asymptomatic ARE	27 (13.8%)
Asymptomatic hemorrhage	1 (0.5%)
No	162 (83.1%)
Symptomatic ARE	5 (2.6%)
Time to ARE, months	6.0 (3.0,30.0)
New CN palsy
No	144 (98.6%)
Permanent	1 (0.7%)
Transient	1 (0.7%)
Not available	49 (25.1%)
New neurological deficit	18 (11.9%)
Not available	44 (22.5%)
Additional radiation	88 (45.8%)
Not available	3 (1.5%)
Time to additional radiation	9.4 (4.5,12.9)
Additional surgery	24 (12.4%)
Not available	2 (1%)
Time to additional surgery	15.9 (5.8,21.8)
Status at last follow-up
Alive	64 (32.8%)
Dead	131 (67.2%)
Clinical follow-up, (months)	17.0 (9.0,31.5)
Radiographic follow-up, (months)	14.5 (6.0,27.4)
Progression-free survival, (months)	8.9 (5.0,15.8)
Overall survival from primary diagnosis, (months)	66.3 (40.5,103.8)
Overall survival from BM diagnosis, (months)	22.0 (12.5,38.3)
Time to brain metastases diagnosis, (months)	35.0 (15.0,65.0)
Number of treated metastases	3.0 (1.0,7.5)

¹n (%); Median (25%,75%)